Alto Neuroscience (ANRO) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Alto Neuroscience to Participate in Upcoming Investor Conferences
Businesswire08:03 ET
One Mind Accelerator Announces Third Cohort of Mental Health Startups
BusinesswireFeb 24 09:03 ET
USPTO Grants Alto Neuroscience Patent for MDD Treatment Covering ALTO-300
TipRanksFeb 19 08:20 ET
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
BusinesswireFeb 19 08:03 ET
Express News | Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
ReutersFeb 19 08:03 ET
Pleasing Signs As A Number Of Insiders Buy Alto Neuroscience Stock
Yahoo FinanceFeb 18 08:48 ET

Comments

Teddy123

Feb 19 07:06

Biotech Patent Analysis

$Alto Neuroscience (ANRO.US)$
The commercial potential is noteworthy for several reasons:
The treatment-resistant depression market represents approximately 30% of MDD patients, creating a substantial addressable market for adjunctive therapies.
The biomarker-guided approach could significantly improve treatment outcomes by identifying likely responders, potentially commanding premium pricing compared to traditional antidepressants.
EEG biomarkers provide an objective, m...

Teddy123

Feb 19 07:06

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

$Alto Neuroscience (ANRO.US)$
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care

Jaguar8

Feb 12 09:10

NEWS PM

$Alto Neuroscience (ANRO.US)$
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
Wednesday, 12th February at 8:03 am
– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample –
– Topline results are expected in mid-2026 –
– The company recently reported an estimated preliminary 2024 year-end cash balance of approximately ...

1

Teddy123

Feb 12 07:18

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

$Alto Neuroscience (ANRO.US)$
Clinical Trial Success: Alto's Novel Depression Treatment Hits Key Milestone in Phase 2b Study

Jaguar8

Dec 11, 2024 07:07

NEWS

$Alto Neuroscience (ANRO.US)$
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for...

1

ANRO Alto Neuroscience

Trade Overview

Capital Trend

News

Comments

Trending Stocks